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Abstract
Background. A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain 
metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to 
develop a clinical risk assessment score.
Methods. Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Of these, 
100 (28.7%) BM in 48 (53.9%) patients responded with either TR (n = 53, 15%) or PP (n = 47, 14%). Differences be-
tween the 2 groups were analyzed and used to develop a risk assessment score (the Bergen Criteria).
Results. Factors associated with a higher incidence of PP vs. TR were as follows: prior radiation with whole brain 
radiotherapy or SRS (P = .001), target cover ratio ≥98% (P = .048), BM volume ≤2 cm3 (P = .054), and primary lung 
cancer vs. other cancer types (P = .084). Based on the presence (0) or absence (1) of these 5 characteristics, the 
Bergen Criteria was established. A total score <2 points was associated with 100% PP, 2 points with 57% PP and 
43% TR, 3 points with 57% TR and 43% PP, whereas >3 points were associated with 84% TR and 16% PP, P < .001.
Conclusion. Based on 5 characteristics at the time of SRS the Bergen Criteria could robustly differentiate between 
PP vs. TR following SRS. The score is user-friendly and provides a useful tool to guide the decision making whether 
to retreat or observe at appropriate follow-up intervals.
Key Points
 • Treatment data predict the risk of pseudoprogression vs. recurrence post-SRS.
 • The Bergen Criteria robustly assesses the risk of pseudoprogression vs. recurrence.
A major challenge in the management of patients with brain 
metastases (BM) treated with stereotactic radiosurgery (SRS) 
is to distinguish radiation necrosis or pseudoprogression (PP) 
from tumor recurrence (TR) for which treatment and prog-
nosis are different1,2 (Figure 1A). TR is due to failed SRS and 
further treatment is needed. PP on the other hand is a sign 
of successful SRS due to radiation induced damage to the 
blood–brain barrier3 and influx of inflammatory cells.4,5 These 
changes lead to increased T1-contrast enhancement on mag-
netic resonance imaging (MRI) mimicking TR, but subside 
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spontaneously without change in treatment.6 Ambiguous 
MRI changes during follow-up are often managed by con-
ducting an additional, early MRI follow-up to see if the 
changes stabilize or subside7,8 and/or to add additional im-
aging techniques9 to try to differentiate between the two. 
MRI perfusion10,11 may show high intratumoral blood per-
fusion in TR and Positron Emission Tomography (PET)12–14 
may show increased uptake of glucose or amino acids in 
TR compared with PP, respectively, but differentiation can 
still be difficult. In some cases a biopsy15 or resection of 
the lesion will provide a definite diagnosis but involves 
the risks associated with a surgical procedure. Moreover, 
a wait and see strategy may lead to delayed treatment in 
cases with TR, whereas immediate treatment may turn out 
to be unnecessary if PP and even harmful if the lesion is 
reirradiated.16
It is well documented that the chance of successful 
SRS is higher if the BM are small,17,18 radiosensitive,19 
previously irradiated20 and treated with optimal dosim-
etry.17,21 Thus, we wanted to investigate whether base-
line tumor- and treatment-related data that are readily 
available in a clinical setting could predict the likelihood 
of PP vs. TR (when follow-up MRI shows increased con-
trast enhancement) and whether these data could be in-
tegrated into a clinical risk assessment score. To achieve 
this, we investigated the predictive value of various 
baseline characteristics at SRS to assess the likelihood 
of PP vs. TR.
Methods
Volumetric tumor change was a secondary end point in a 
prospective study evaluating quality of life changes fol-
lowing Gamma Knife Surgery (GKS) for BM.22 Treatment 
and follow-up MRI of 97 consecutive patients treated for a 
total of 406 BM with Gamma Knife Perfexion at Haukeland 
University Hospital between 2009 and 2011 were pro-
spectively collected and analyzed. Two hundred and 
twenty-five BM were treated initially (iSRS), 160 BM at sub-
sequent GKS (sSRS) as distant failures, and 21 BM were 
treated with repeat-SRS due local failure (LF) following 
iSRS. In the present study, we included all BM that either 
pseudoprogressed (47 BM) or recurred (53 BM), Figure 1B.
Ethical approval was obtained from the Regional Ethical 
Committee for Medical Research (REK, 2010/801) and 
written informed consent was obtained from all patients.
SRS Treatment: Radiation Doses Used for Various 
Sizes of Metastases
BM were treated with a prescribed dose of 20–25 Gy 
(n = 340), and 16–18 Gy if prior radiation, large total tumor 
volume (>10–15  cm3) and/or close proximity to critical 
structures (n = 50). For 16 (4%) BM the prescription dose 
was ≤15 Gy due to prior SRS (n = 9), prior whole brain ra-
diotherapy (WBRT) (n = 3), large tumor volume (n = 2), or 
tumor location (n = 2).
Follow-up Schedule and Volume Measurements 
of SRS Treated BM
The BM volumes on MRI T1-contrast enhanced imaging (MRI-
T1-C) were measured utilizing the GammaPlan software 
(Elekta, Stockholm, Sweden) at GKS and during follow-up 
at 1 and 3  months, then every third month post-GKS until 
September 30, 2019 or death. Follow-up images were available 
for 348 (85.7%) out of 406 BM in 87 (89.7%) of the 97 patients 
(95.6% of the 91 patients alive at first MRI 1 month post-SRS). 
Two patients (2.1%) are still alive in September 2019.
Volumetric Tumor Response—Definition of PP 
vs. TR
The volume changes over time on MRI-T1-C from SRS until 
LF leading to new treatment (surgery, WBRT, or re-SRS) or 
until last follow-up/death was used to define PP from TR. 
Local failures that were retreated with a second course of 
SRS were evaluated as separate lesions/treatments and 
volume changes from re-SRS were recorded.
All BM followed 1 of 4 principal response patterns: ei-
ther continuous reduction in size (n = 238, 68%), transient 
increase in volume defined as PP (n  =  47, 14%), delayed 
Importance of the Study
A key task in the follow-up of patients with 
brain metastases (BM) treated with stereo-
tactic radiosurgery (SRS) is to differentiate 
pseudoprogression (PP) from recurrence, for 
which treatment and prognosis are different. 
Nearly 1/3 of BM treated with SRS will display 
increased contrast enhancement on standard 
magnetic resonance imaging; either tempo-
rarily due to successful SRS or progressively 
due to failed SRS. Previous studies have fo-
cused on sophisticated imaging techniques to 
distinguish radiation induced changes from 
recurring tumors. The present study is the 
first to evaluate clinical data to predict the 
risk of developing PP vs. recurrence. Known 
predictors for successful SRS (small volume, 
radiosensitive histology, prior radiation, and 
optimal dosimetry) intuitively predict higher 
risk of PP vs. recurrence. Based on the presence 
or absence of these 4 predictors the Bergen 
Criteria was established. It estimates with high 
accuracy the likelihood of PP vs. recurrence, is 
user-friendly and cost-free. Further validation 
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growth defined as TR (n = 53, 15%), or no response with 
continuous growth (n = 10, 3%) (B.S.S. et al., unpublished 
manuscript). Only 2 (2%) of the BM were resected after 
SRS yielding biopsy material. Figure 1C illustrates the dis-
tribution of the different volumetric response patterns for 
all 87 patients (348 BM) with follow-up MRI.
Patient Population Used to Develop a Risk 
Assessment Score for the Likelihood of PP vs. TR
We included all 48 (55.1%) out of the 87 patients with fol-
low-up images of at least 1 BM that either pseudoprogressed 
(47 BM) and/or recurred (53 BM), Figure  1D. Thus, 100 
(28.7%) out of 348 BM were included of which 86 were 
treated with iSRS and 14 of these with subsequent re-SRS 
due to TR. The mean age of the 48 included patients was 
60 years (range 39–86 years) and 22 (45.8%) were males.
Tumor Subtypes
The primary cancer site was lung (n = 21 patients [43.8%]), 
melanoma (n  =  7 [14.6%]), renal (n  =  5 [10.4%]), breast 
(n = 4 [8.3%]), colorectal cancer (CRC, n = 9 [18.8%]), or un-
known (n = 2 [4.2%]).
Prior Whole Brain Radiotherapy and 
Immunotherapy
Twelve (25%) of the 48 patients that had previously been 
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Figure 1 (A) Illustration of 2 potential response patterns for brain metastases (BM) treated with stereotactic radiosurgery (SRS): 
pseudoprogression (PP) and tumor recurrence (TR). (B) Individual tumor volume response curves on contrast enhanced T1-weighted MRI at ster-
eotactic radiosurgery (time: 0) and during follow-up for (A) 53 pseudoprogressing tumors and (B) 47 recurring tumors. (C) Venn diagram of 87 out of 
97 patients with follow-up MRI of a total of 348 BM post-radiosurgery. The diagram illustrates the proportion of patients with BM responding with 
the 4 distinct volumetric response patterns on contrast enhanced MRI: tumor recurrence (red), pseudoprogression (green), continuous tumor 
volume reduction (blue), and continuous tumor growth (orange). (D) Venn diagram of patients (n = 48) included in the development of the Bergen 
Criteria. Tumor type (lung cancer vs. other primary sites) and prior irradiation history for patients in 3 cohorts are illustrated: 21 (43.8%) patients 
with 28 recurrences (red), 12 (25.0%) patients with 22 pseudoprogressions (green), and 15 (31.2%) patients with some recurrences (n = 25 BM) and 
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occurred in the 12 patients with prior WBRT. None of the 
patients in this cohort were treated with immune check-
point inhibitors at the time of SRS.
Repeat-SRS
Eleven (22.9%) of the 48 patients underwent iSRS (n = 14 
BM) and later re-SRS (n  =  14 BM) for the same BM due 
to recurrence. Post-re-SRS 12 of the 14 BM subsequently 
pseudoprogressed and 2 re-recurred. The remaining 37 
(77.1%) patients only underwent iSRS for 72 BM; 12 pa-
tients had at least 1 BM that pseudoprogressed, 20 patients 
had at least 1 BM that recurred, and 5 patients had a mix-
ture of PP and TR.
The Bergen Criteria
All 47 BM responding with PP were compared with the 53 
BM responding with TR. Baseline tumor- and treatment-
related characteristics found to be associated with devel-
opment of PP compared with TR were used to design a risk 
assessment score to estimate the likelihood of PP vs. TR 
(the Bergen Criteria). The score was refined by choosing 
predictive factor splits for maximizing practical use.
Statistics
To analyze differences between BM responding with PP 
vs. recurring BM we used Student’s t-test for continuous 
variables (baseline BM volume, prescription dose, max-
imum dose, target cover ratio, 12 Gy normal brain volume, 
total steroid dose, and time from SRS until increase in 
BM volume on MRI-T1-C) and Pearson’s χ 2 test for catego-
rical variables (primary cancer site, prior treatment with 
SRS and/or WBRT, and steroid medication). For variables 
found to be significantly associated with PP vs. TR we 
used Pearson’s χ 2 test to refine the score: prior SRS (yes 
or no), prior WBRT (yes or no), BM volume ≤2  cm3 (yes 
or no), target cover ratio ≥98% (yes or no), primary lung 
cancer (yes or no), and to assess the predictive value of 
the Bergen Criteria. Overall survival (OS) was analyzed by 
the Kaplan–Meier method. Date for end-of-follow-up was 
September 30, 2019.
Results
The BM in the 4 response groups described above dif-
fered significantly in volume, prescribed dose, and target 
cover ratio at SRS (Table  1). There was a striking simi-
larity between BM with favorable outcomes (continuous 
tumor volume reduction or PP) and BM with unfavorable 
outcomes (continuous tumor growth or TR). BM with a 
favorable outcome were generally small (mean volume 
≤2.3 cm3) and treated with high target cover ratio (mean 
target cover ratio ≥ 98%) at SRS. On the other hand, BM 
with an unfavorable outcome were large (mean volume 
≥3.5 cm3) and less optimally covered at SRS (mean target 
cover ratio <98%). We found significant differences when 
comparing BM in the PP group with the TR group: First, 
they were significantly smaller (mean BM volume 2.3 vs. 
4.8 cm3, P =  .015) and more completely covered with the 
prescribed dose (mean target cover ratio 98.6% vs. 97.6%, 
P = .026). These differences at baseline were used to pre-
dict the likelihood that increased MRI-T1-C enhancement 
following SRS was due to PP or recurrence.
Baseline Tumor Volume as Predictor for PP vs. TR
For practical reasons we used 2  cm3 as cutoff. It corres-
ponds to a tumor diameter of 1.5  cm that can be easily 
assessed on MRI. We found that BM less than 2 cm3 were 
more likely to develop PP than larger BM. Of the 47 BM 
  
Table 1  Baseline Characteristics for Brain Metastases (BM) According to 4 Principle Tumor Volume Response Curves on Contrast Enhanced 
T1-Weighted-MRI Following Stereotactic Radiosurgery (SRS) in 348 of 406 BM With Follow-up MRI (in 87 of 97 Consecutive Patients) at Haukeland 
University Hospital in Bergen (Norway) Between 2009 and 2011
Characteristic Response Curve Group n (%) Mean P Value
Tumor volume at SRS 
(cm3)
Continuous tumor volume reduction 238 (68) 1.4 <.001
Temporary increase in tumor volume (PP) 53 (15) 2.3
Delayed growth (TR) 47 (14) 4.8
Continuous tumor growth 10 (3) 3.5
Prescription dose at SRS 
(Gy)
Continuous tumor volume reduction 238 (68) 20.5 <.001
Temporary increase in tumor volume (PP) 53 (15) 20.2
Delayed growth (TR) 47 (14) 19.3
Continuous tumor growth 10 (3) 15.9
Target cover ratio at SRS 
(%)
Continuous tumor volume reduction 238 (68) 98.9 <.001
Temporary increase in tumor volume (PP) 53 (15) 98.6
Delayed growth (TR) 47 (14) 97.6
Continuous tumor growth 10 (3) 96.0
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displaying PP, 32 (68.1%) vs. 15 (31.9%) were ≤2 cm3, or less 
than 1.5 cm in diameter vs. >2 cm3 (P = .054, χ 2 = 3.7, df = 1, 
and Cramer’s V: 0.192). Similar numbers for recurring BM 
were 26 (49.1%) vs. 27 (50.9%), Figure 2A.
Target Cover Ratio at SRS as Predictor for PP 
vs. TR
BM responding with PP had significantly more often a 
higher coverage with the prescribed dose at SRS com-
pared with recurring BM. Using 98% as cutoff we found 
a significantly higher incidence of PP vs. recurrence if the 
target cover ratio was ≥98%. Of 46 BM displaying PP, 37 
(78.7%) vs. 10 (21.3%) had a target cover ratio of ≥98% 
vs. <98% and for recurring BM 32 (60.4%) vs. 21 (39.6%), 
P = .048, χ 2 = 3.9, df = 1, and Cramer’s V: 0.198, Figure 2B.
Prior Radiation Treatment as Predictor for PP 
vs. TR
Prior IR was a strong predictor of PP vs. TR (P  =  .001, 
χ 2 = 13.7, df = 2, and Cramer’s V: 0.370). In the PP group, 10 
BM (21.3%) were previously treated with SRS, 17 (36.2%) 
with WBRT whereas 20 (42.6%) were not previously irradi-
ated. On the contrary, in the TR group, only 1 BM (1.9%) 
was previously treated with SRS, 13 (24.5%) with WBRT, 
and 39 (73.6%) were not previously irradiated, Figure 2C.
Primary Cancer Site as Predictor for PP vs. TR
We found that BM in the PP group more often originated 
from primary lung cancer than from other primaries com-
pared with BM in the TR group (P = .084, χ 2 = 3.0, df = 1, and 
Cramer’s V: 0.173). The primary cancer site was lung for 24 
(57.1%) of the 47 BM in the PP group and 18 (34.0%) of the 
53 BM in the TR group, Figure 2D.
Time Frame for Detection of PP vs. TR
The mean time from SRS until increased contrast en-
hancement on MRI was detected was significantly shorter 
for PP than TR, 5.1  months (SD 4.1, range 1–18  months) 
vs. 8.4 months (SD 6.5, range 3–36 months), respectively, 
P = .003. The mean time for the contrast enhancement to 
subside in PP was 3.2 months (SD 1.4, range 1–6 months). 
PP occurred within 6 months of SRS for 37 (78.7%) of 47 
BM and more than 6  months post-SRS for 10 (21.3%). 
Similar numbers for TR are 31 (58.5%) and 22 (41.5%) of 53 
BM, respectively (P = .030, χ 2 = 4.7, df = 1, and Cramer’s V: 
0.216).
Steroid Treatment as Predictor for PP vs. TR
Neither the use of steroids at SRS (yes vs. no; P = .897) nor 
the steroid dose used at baseline (categorical variables: 0 
vs. 1–4 vs. >4 mg dexamethasone; P = .748/continuous var-
iable: total steroid dose; P = .930) was significantly associ-
ated with development of PP (mean 4.0 mg, SD 6.0, range 
0–16 mg) vs. TR (mean 5.0 mg, SD 5.2, range 0–16 mg).
The Bergen Criteria for Assessing the Risk of PP 
vs. Recurrence
Factors associated with a higher incidence of PP vs. TR used 
were as follows (1) prior SRS, (2) prior WBRT, (3) target 
cover ratio ≥98%, (4) BM volume ≤2 cm3, and (5) primary 
lung cancer vs. other primaries. Based on the presence 
(0) or not (1) of these 5 parameters, the Bergen Criteria for 
risk assessment of PP vs. TR was established (Table 2). The 
total score ranges from 0 to 5 points. A score of 0 corres-
ponds with high risk of PP vs. TR, whereas a score of 5 cor-
responds with a low risk of PP vs. TR. For simplicity, the 
predictive value of 4 Bergen Criteria groups, total score <2, 
2, 3, and >3 points, respectively, was calculated (Table 3).
A score of <2 point was associated with a 100% likeli-
hood of PP, 2 points with 57% risk of PP vs. a 43% risk of TR, 
3 points with a 57% risk of TR vs. 43% risk of PP whereas >3 
points were associated with 84% likelihood for TR vs. 16% 
for PP (χ 2 = 24.6, df = 3, P < .001, and Cramer’s V = 0.496).
All BM with Bergen Criteria score >3 originating from 
primary CRC (n = 6), lung cancer (n = 3), or unknown pri-
mary (n = 2) belonged to the TR group vs. 71% (n = 10) of 
the 15 BM origination from other primaries (melanoma, 
renal, and breast cancer). All 7 BM with Bergen Criteria >3 
and contrast enhancement occurring >6 months after SRS 
belonged to the TR group vs. 14 of the 18 BM occurring 
≤6 months after SRS.
The Bergen Criteria is applicable also when excluding 
the 13 retreated BM. For the 87 BM that were not retreated 
Bergen Criteria 0–1 were associated with 100% PP and 
Bergen Criteria of 2, 3, and 4–5 with 52%, 42%, and 12% PP, 
respectively, P < .001).
The mean scores for the Bergen Criteria for the 4 re-
sponse patterns, continuous reduction in size, PP, delayed 
growth (TR), and continuous growth, are 2.7 (SD: 0.72, 
range 1–4), 2.3 (SD: 0.95, range: 1–4), 3.2 (SD: 0.78, range 
2–4), and 3.1 (SD: 0.74, range 2–4), respectively (χ 2: 20.5, df: 
3, P < .001).
Treatment at PP and TR Following SRS
None of the BM responding with PP were resected, 43 
(91.5)% were asymptomatic, and 4 (8.5%) were managed 
with a short course of dexamethasone treatment.
Twenty-nine (52.7%) out of 53 TRs were treated conserv-
atively with observation, 18 (32.7%) were retreated with 
SRS, 2 (3.6%) were resected with biopsy confirmed TR, and 
4 (7.3%) were treated with WBRT.
Overall Survival
The OS for patients with TR, PP, or both was significantly 
longer than for the 49 patients with MRI follow-up that ex-
perience neither TR nor PP, P < .001. The median OS for the 
last group was only 4.5 months (95% CI 3.8–5.1) compared 
with 11.7 months (95% CI 6.6–16.8) for the 21 TR only pa-
tients, 10.9 months (95% CI 3.9–17.9) for the 12 PP only pa-
tients, and 15.4 months (95% CI 12.4–18.5) for the mixed 
response group, respectively. The OS for the 10 patients 
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Figure 2 The number of brain metastases (BM) that responded to stereotactic radiosurgery (SRS) with pseudoprogression or tumor recurrence 
with: (A) Baseline volume ≤2 cm3 vs. >2 cm3. (B) Target cover ratio at SRS <98% vs. ≥98%. (C) Prior treatment with SRS, whole brain radiotherapy ± 
SRS vs. no prior radiation treatment. (D) Primary lung cancer origin vs. other origin than lung cancer. (E) Overall survival curves for patients with 
(a) at least 1 BM that recurred (TR) (red), (b) at least 1 BM that pseudoprogressed (PP) (green), (c) a mixture of TR and PP (violet), (d) no TR nor PP 
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Differentiating TR from PP is a daily clinical challenge and 
of utmost importance to avoid both unnecessary treat-
ments and treatment delays. More than 50% of the pa-
tients in our material experienced either TR or PP of at least 
one of their BM, which is in line with previous studies.23 
One could argue that PP is due to successful or even 
“overtreatment” with SRS while TR reflects failed SRS. 
Utilizing treatment data is a novel way of distinguishing PP 
from TR. From our data we found 4 distinct baseline char-
acteristics at SRS distinguishing BM responding with PP 
from recurring BM. They were more often previously ir-
radiated, significantly better covered with the prescribed 
dose at SRS, smaller and more often originating from pri-
mary lung cancer. Using this information we were able 
to create a simple score which robustly distinguished PP 
and TR in a large number of patients. All BM in our study 
responding either with PP or TR with a score less than 2 
belonged to the PP group. For the BM with a score more 
than 3, 84% belonged to the TR group. The Bergen Criteria 
is based on easily accessible tumor- and treatment-related 
characteristics available in the patient’s medical record and 
does not require special training or additional advanced 
imaging techniques. Furthermore, the Bergen Criteria is 
based purely on known predictors2 for successful SRS 
and is therefore intuitive. We know when we treat a large 
radioresistant brain metastasis with an incomplete target 
cover ratio that the chance of success is lower than if we 
treat a small, previously irradiated radiosensitive brain me-
tastasis with optimal target cover ratio. The Bergen Criteria 
works as follows. If a brain metastasis ≤2 cm3 originating 
from lung cancer that was irradiated with WBRT prior to 
SRS starts to enlarge on MRI-T1-C, we can be 100% certain 
that this is due to PP if the brain metastasis was completely 
covered with the prescribed dose (Bergen Criteria score 0). 
Similarly, if a brain metastasis >2 cm3 at SRS originating 
from melanoma and not previously irradiated starts to 
enlarge following SRS, we can be 84% confident that the 
BM are recurring if the BM were not fully covered at SRS 
(Bergen Criteria score 5). The likelihood might further be 
estimated to 100% if the primary cancer is CRC, unknown 
or lung or the contrast enhancement is detected more than 
6  months post-SRS, but this needs to be confirmed in a 
larger cohort of patients.
The Bergen Criteria can classify all BM enlarging fol-
lowing SRS either as most likely due to PP or most likely 
due to TR. Depending on the total score the risk of TR varies 
from 0% to 84% and the risk of PP from 16% to 100%. If TR is 
most likely it may be an advantage to confirm whether an 
enlarging tumor on MRI-T1-C follow-up is due to PP or TR 
with additional imaging such as the T1/T2 mismatch8,24 be-
fore initiating treatment. If the tumor size is comparable on 
contrast enhanced T1- and T2-weighted MRI images, this is 
most likely to represent the true tumor size and hence TR. 
If however, the BM are smaller on the T2- than T1-contrast 
series, the difference in size on the T1 vs. T2 is most likely 
due to changes in the normal brain–blood circulation sur-
rounding the tumor and hence reflect PP. MRI perfusion 
and PET may be of value as reduced blood flow and uptake 
of glucose or amino acids strengthens the suspicion of PP 
vs. TR. Advanced imaging methods and biopsies evaluate 
the tumor at the time of progression or PP. However, the 
Bergen Criteria can estimate the chance of success based 
  
Table 3 The Likelihood of Pseudoprogression (PP) vs. Tumor Recurrence (TR) as a Cause of Tumor Enlargement on Contrast Enhanced 
T1-Weighted-MRI Following Stereotactic Radiosurgery (SRS) (n = 100 Brain Metastases in 48 Patients) According to the Bergen Criteria at  
Haukeland University Hospital in Bergen (Norway) Between 2009 and 2011
The Bergen Criteria Total BM With PP or TR 
(N = 100)
Likelihood of PP (%)  
(n = 47)
Likelihood of TR (%)  
(n = 53)
N (%) % n (% of PPs) % n (% of TRs)
0–1 12 (12.0) 100 12 (25.5) 0 0 (0.0)
2 28 (28.0) 57 16 (34.0) 43 12 (22.6)
3 35 (35.0) 43 15 (31.9) 57 20 (37.7)
4–5 25 (25.0) 16 4 (8.5) 84 21 (39.6)




Table 2 The Pseudoprogression (PP) Risk Assessment Score (the 
Bergen Criteria), With Total Range: 0 (Low Risk of PP) to 5 (High Risk of 
PP), Is Defined as the Sum of the Scores on 5 Baseline Characteristics 
Based on 348 of 406 BM With Follow-up MRI (in 87 of 97 Consecutive 
Patients) at Haukeland University Hospital in Bergen (Norway) 
Between 2009 and 2011




 Primary lung cancer Yes No
 BM volume ≤2 cm3 (≤1.5 cm in diameter) Yes No
 Target cover ratio >98% Yes No
 Prior SRS to the same BM Yes No
 Prior WBRT Yes No
BM, brain metastases; MRI, magnetic resonance imaging; SRS, stere-
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on treatment-related factors alone and thus adds value to 
the existing methods by combining information at the time 
of SRS with information at the time the BM volume starts 
to increase on MRI-T1-C post-SRS.
PP is considered a good prognostic sign.23 PP is often 
asymptomatic (>90% in our study) and symptoms usually 
respond to treatment with a short course of steroids. In 
rare cases, surgery may be necessary to relieve symptoms. 
Nevertheless, surgery has an inherent risk of complica-
tions, thus a wait and see strategy is preferred if one sus-
pects PP.2 We suggest that the Bergen Criteria may be used 
to tailor appropriate follow-up intervals. If a BM enlarges 
on MRI-T1-C following SRS with a Bergen Criteria score 
<2, the patient may continue with standard 3 months fol-
low-up intervals due to a high likelihood of PP. Conversely, 
a Bergen Criteria score >3 calls for an early MRI follow-up 
or immediate retreatment. If the score is 2 or 3, the patient 
may be followed at intermediate intervals (6–8 weeks) or 
the patient should be offered additional imaging with per-
fusion MRI or PET.
Radiation is the main cause of PP in BM patients. For a 
brain metastasis to achieve a Bergen Criteria score <2 it 
must have been previously irradiated either with SRS, 
WBRT, or both. There are few reports on PP following 
WBRT alone. PP seems to occur when WBRT is combined 
with SRS25 and when high-dose SRS is used alone or re-
peated for the same brain metastasis. Thus, the total ac-
cumulated dose to the tumor and normal brain is clearly 
related to the development of PP. In the present study, the 
likelihood of PP increased if the brain metastasis was com-
pletely covered with the prescribed dose independent of 
the dose itself. This implies that the minimum dose to the 
tumor margins, rather than the maximum (or prescribed) 
dose, may be the most important dosimetric factor for 
successful SRS and thereby risk of TR vs. PP. Radiation 
damage to the tumor induces an inflammatory response 
which seems to play a role in the development of PP. The 
more complete the target cover ratio is at SRS, the more 
tumor cell death is induced by radiation which again might 
induce a stronger antitumor immune response than if the 
target coverage ratio is lower.
PP is often observed in patients treated with immuno-
therapy.5 Of note, none of the patients in the cohort used 
to derive the Bergen Criteria were treated with immuno-
therapy. With their increasingly common use in a wide va-
riety of malignancies, there may be some differences in the 
PP and TR percentages, depending on whether or not these 
drugs are being employed as systemic therapy. A  retro-
spective study showed that immunotherapy in combination 
with SRS increased the local control rate and risk of radia-
tion necrosis (RN) when immunotherapy was administered 
during or after SRS compared with when it was adminis-
tered before SRS.26 Recent reviews found inconclusive dif-
ferences in LC rates and risk of RN when they compared 
combined SRS and immunotherapy with SRS alone.27,28 
Nevertheless, due to the potential synergistic effect of SRS 
in combination with checkpoint inhibitors, the predictive 
value of the Bergen Criteria needs to be confirmed in a co-
hort receiving a combination of these 2 treatments.
Tumor size is the main limitation for SRS. Smaller BM 
respond better to SRS and therefore also more often re-
spond with PP than larger BM. However, BM from different 
primaries represent different diseases. Lung cancer BM 
are radiosensitive and respond well to SRS with a corre-
sponding high rate of PP compared with BM from other 
primary cancer sites. Moreover, lung cancer patients have 
a high-risk developing BM and are thus routinely screened 
for BM. Consequently, BM in lung cancer patients are likely 
to be detected when they are smaller compared with BM in 
patients with more radioresistant primaries.
The significantly longer survival observed for patients ex-
periencing TR, PP, or both compared with patients that do not 
suggests that the Bergen Criteria may be valid also for long-
term survivors. However, as only 2 of 97 patients have more 
than 5 years OS in the present study, longer-term data on large 
datasets will need to be scrutinized to see if the Bergen Criteria 
are as infallible in patients who are in long-term follow-up as 
they appear to be in the short-term follow-up cohorts.
The strength of the study is the prospective design, the 
national referral area and the high compliance rate with 
complete MRI follow-up until death for more than 95% 
of the patients. Still, the relatively low number of BM in-
cluded is a limitation. Secondly, the Bergen Criteria is de-
rived in a cohort treated with SRS before the introduction 
of immunotherapy. This is a potential shortcoming that re-
quires cautioning for those who might employ the Bergen 
Criteria in her/his own clinic to predict the future for indi-
vidual patients. Thirdly, temporary volume increase on 
MRI-T1-C was used as definition for PP in the present study 
and delayed growth as definition for TR; without histolog-
ical confirmation except for 2 cases with TR. Nevertheless, 
the volumetric curves used represent the final outcome for 
all BM as all patients are followed for more than 5 years or 
until death. Importantly, none of the BM responding with 
temporary volume increase (PP) recurred at a later stage. 
Finally, in the present study, BM are used as the observa-
tion unit and thus assessed as independent of the patient 
even though some patients had more than 1 BM and a 
dependency between BM in the same patient therefore is 
likely. Independent assessment of observations of BM in 
the same patient may lead to excessive statistical signif-
icance. Moreover, a prognostic index will always be ad-
justed to the material from which it has been developed 
with an excessively good predictability.
The Bergen Criteria is user-friendly, intuitive, and cost-
free. It estimates with high accuracy the likelihood of 
PP, a sign of successful treatment, vs. the risk of failed 
treatment based on 4 simple and readily available treat-
ment characteristics. The Bergen Criteria may be of help 
when deciding whether to retreat or observe, informing 
patient and choosing an appropriate follow-up interval. 
Ultimately, it may lead to reduced use of expensive PET/
specialized MRI sequences and reduce the number of 
treatment delays and unnecessary surgeries. Larger 
studies are however needed to validate our results. 
The Bergen Criteria may be extended to additional data 
sources, which may lead to a refined score for subtypes of 
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